Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, double dummy, parallel group study comparing Fluticasone propionate / formoterol fumarate (flutiform) 250/10 mcg (2 puffs BID) and flutiform 125/5 mcg (2 puffs BID) versus Formoterol fumarate dihydrate (Atimos) 12 mcg (1 puff BID) in subjects with chronic obstructive pulmonary disease (COPD).

Trial Profile

A randomised, double-blind, double dummy, parallel group study comparing Fluticasone propionate / formoterol fumarate (flutiform) 250/10 mcg (2 puffs BID) and flutiform 125/5 mcg (2 puffs BID) versus Formoterol fumarate dihydrate (Atimos) 12 mcg (1 puff BID) in subjects with chronic obstructive pulmonary disease (COPD).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 15 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
    • 30 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2017 According to a Vectura media release, data from trial will be presented during 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top